Melane Sampson, Author at BioTuesdays

Developments

Jupiter spotlights critical advancement of JOTROL v conventional resveratrol

Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the critical advancement of its proprietary resveratrol platform, JOTROL, compared to conventional resveratrol formulations, citing breakthrough bioavailability and...

July 23, 2025

Feature

Nimbus designing potential best-in-class small molecule medicines for difficult-to-drug targets

Closely held Nimbus Therapeutics is designing and developing precisely tailored small molecule medicines for challenging targets by leveraging a unique strategy that combines computational chemistry technologies with...

July 22, 2025

Developments

EC grants marketing authorization for Autolus’ AUCATZYL for rr/B-ALL

Autolus Therapeutics (NASDAQ: AUTL) has announced that the European Commission (EC) has granted marketing authorization for AUCATZYL for the treatment of adult patients aged 26 and over with relapsed or refractory B...

July 21, 2025

Developments

USPTO grants Autonomix patent for smart torquer device

Autonomix Medical (NASDAQ: AMIX) has announced that the United States Patent and Trademark Office (USPTO) has issued a patent for its smart torquer device. The device is designed to enhance the manipulation of elongated...

July 21, 2025

Developments

Cuprina names Dr. Ronald Sherman as medical and scientific director; secures FDA-approved medical maggot license

Cuprina Holdings (NASDAQ: CUPR) has announced the appointment of Dr. Ronald Sherman, a leading innovator in maggot debridement therapy (MDT), as medical and scientific director, effective September 2025—securing the...

July 21, 2025

Developments

Knight files NDS for CREXONT in Canada

Knight Therapeutics (TSX: GUD) has announced that its new drug submission (NDS) for CREXONT—a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease—has...

July 18, 2025

Executive Moves

Bryan Baum joins Senti’s BOD

Senti Bio (NASDAQ: SNTI) has announced the appointment of entrepreneurial leader and investor Bryan Baum to its board of directors (BOD). Mr. Baum is the co-founder and managing partner of K5 Global. His portfolio...

July 18, 2025

Developments

Ekso Bionics launches virtual eksoUniversity to support CE for PTs and PTAs

Ekso Bionics (NASDAQ: EKSO) has announced the launch of eksoUniversity, a new platform providing continuing education (CE) courses to physical therapists (PTs) and physical therapy assistants (PTAs) across the U.S. Most...

July 18, 2025

Developments

Cell One Partners’ video series: Dr. Stephen Chang reflects on 40 years of innovation in cell and gene therapy

In the latest episode of consulting company Cell One Partners’ video series—Cell One Insights—on cell and gene therapy, Stephen Chang, PhD—a human geneticist and partner at Cell One Partners—shares insights from his 40...

July 15, 2025

Executive Moves

Iovance appoints Corleen Roche as CFO

Iovance Biotherapeutics (NASDAQ: IOVA) has announced the appointment of Corleen Roche as chief financial officer (CFO), effective August 6, 2025. Ms. Roche brings three decades of biotech and life sciences industry...

July 15, 2025

Author - Melane Sampson

Jupiter spotlights critical advancement of JOTROL v conventional resveratrol

Nimbus designing potential best-in-class small molecule medicines for difficult-to-drug targets

EC grants marketing authorization for Autolus’ AUCATZYL for rr/B-ALL

USPTO grants Autonomix patent for smart torquer device

Cuprina names Dr. Ronald Sherman as medical and scientific director; secures FDA-approved medical maggot license

Knight files NDS for CREXONT in Canada

Bryan Baum joins Senti’s BOD

Ekso Bionics launches virtual eksoUniversity to support CE for PTs and PTAs

Cell One Partners’ video series: Dr. Stephen Chang reflects on 40 years of innovation in cell and gene therapy

Iovance appoints Corleen Roche as CFO

Subscribe